Abstract:
The present invention provides a recombinant expression vector which expresses M cell targeting peptide CKS9 conjugated IL2 protein, and a recombinant expression vector conjugated recombinant lactococcus lactis, thereby being able to produce M cell targeting peptide CKS9 conjugated T cell growth factor protein; more efficiently pass through the M cells on intestinal Payer′s Patch surface; be delivered to T cells in the lower part; and activate the T cells. Therefore, the present invention can provide edible vaccines for immunity enhancing which can strongly induce a mucosal immune response.
Abstract:
본 발명은 가금 티푸스 감염에 저해활성이 있는 페디오코커스 아시딜락티시 PA GS 변이균주 ( Pediococcus acidilactici PA GS, 수탁번호 KCTC18229P) 균주, 이의 제조방법 및 이를 포함하는 가금 티푸스 예방 또는 치료용 약학 조성물 및사료 조성물에 관한 것으로, 본 발명의 항균력이 증진된 유산균의 육종방법은 종래의 뉴클레오티드 단위의 돌연변이 유발법보다 직접적인 진화를 유도하고 여러 특징에 걸쳐 포괄적으로 다양한 돌연변이를 발생시킴으로 야생형 페디오코커스 아시딜락티시에 비해 우수한 살모넬라 갈리나룸 ( Salmonella gallinarum ) 저항성을 지닌 페디오코커스 아시딜락티시 PA GS 돌연변이체를 생산할 수 있으며, 이를 포함한 조성물을 가금 티푸스 예방 및 치료용 약학 조성물 및 사료용 조성물로 활용할 수 있다.
Abstract:
The present invention provides novel Lactobacillus plantarum strains which suppress E. coli diarrhea and a method for producing the same and relates to a pharmaceutical composition and a feed composition containing the same for preventing or treating E. coli diarrhea. A method for breeding lactic acid bacteria with enhanced antibacterial ability induces direct evolution compared with an existing mutation method of a nucleotide unit and generates various mutants in various characteristics, thereby producing Lactobacillus plantarum GS1 mutants with superior E. coli K99 resistance than wild type Lactobacillus plantarum. A composition containing the Lactobacillus plantarum strains is used as a pharmaceutical composition and a feed composition.
Abstract:
The present invention relates to microcapsules containing Lactobacillus sp. microbes and a method for manufacturing the same. Provided is a method for manufacturing microcapsules of Lactobacillus salivarius 29 (LS29) and Lactobacillus plantarum 25 (LP25) with long-term survival rate in gastrointestine.
Abstract:
PURPOSE: A transdermal peptide is provided to promote body delivery of large drug molecules. CONSTITUTION: A pore penetration peptide is SSHTISF, FPQPPQR, AFTPAKT or SPWIPAV. The transdermal peptide is SSHTISF, FPQPPQR, AFTPAKT or SPWIPAV. The SSHTISF peptide is ST1 peptide(Ser-Ser-His-Thr-Ile-Ser-Phe). The FPQPPQR peptide is ST2 peptide(Phe-Pro-Gln-Pro-Pro-Gln-Arg). The AFTPAKT peptide is ST2 peptide(Ala-Phe-Thr-Pro-Ala-Lys- Thr). The SPWIPAV peptide is ST4 peptide(Ser-Pro-Trp-Ile-Pro-Ala-Val). [Reference numerals] (AA) Repeat of biopanning round(1-3 times); (BB) Random transdermal administration of phage-peptide library into rat; (CC) Blood collection through heart at predetermined time after administration to collect skin penetrating phage; (DD) Amplificatioin of phage mixture collected from E.coli ER2738; (EE) Selecting each recombinant phage from biopanning of third round and determining peptide-coding nucleotide sequence; (FF) Peptide sequence identification from nucleotide sequence